|
1
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasly MB, Chirieac LC, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He L: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mominioni L, Imperatori A, Rovera F,
Ochetti A, Torrigiotti G and Paolucci M: Stage I nonsmall cell lung
carcinoma: Analysis of survival and implications for screening.
Cancer. 89 (11 Suppl):S2334–S2344. 2000. View Article : Google Scholar
|
|
4
|
National Lung Screening Trial Research
Team, ; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD,
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD:
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Lung Screening Trial Research
Team, ; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan
F, Fagerstrom RM, Gareen IF, Gierada DS, et al: Results of initial
low-dose computed tomographic screening for lung cancer. N Engl J
Med. 368:1980–1991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Snowsill T, Yang H, Griffin E, Long L,
Varley-Campbell J, Coelho H, Robinson S and Hyde C: Low-dose
computed tomography for lung cancer screening in high risk
populations: A systematic review and economic evaluation. Health
Technol Assess. 22:1–276. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Veronesi G: Lung cancer screening: The
European perspective. Thorac Sury Clin. 25:161–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okarnura K, Takayama K, Izumi M, Harada T,
Furuyama K and Nakanish Y: Diagostic value of CEA and CYFRA 21-1
tumor markers in primary lung cancer. Lung Cancer. 80:45–49. 2013.
View Article : Google Scholar
|
|
9
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnosis, monitoring and therapeutics-A
comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pardini B, Sabo AA, Birolo G and Calin GA:
Noncoding RNAs in extracellular fluids as cancer biomarkers: The
new frontier of liquid biopsies. Cancers (Basel). 11:11702019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larrea E, Sole C, Manterola L, Goicoechea
I, Armesto M, Arestin M, Caffarel MM, Araujo AM, Araiz M,
Fernandez-Mercado M and Lawrie CH: New concepts in cancer
biomarkers: Curculating miRNA in liquied biopsies. Int J Mol Sci.
17:6272016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C,
Wang C, Ren Z, Zhao Y, Wu S, et al: Identification of ten serum
microRNAs from a genome-wide serum micreRNA expression profile as
novel noninvasive biomarkers for nonsmall cell lung cancer
diagnosis. Int J Cancer. 130:1620–1628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nadal E, Truini A, Nakata A, Lin J, Reddy
RM, Chang AC, Ramnath N, Gotoh N, Beer DG and Chen G: A novel serum
4-microRNA signature for lung cancer detection. Sci Rep.
5:124642015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lv S, Xue J, Wu C, Wang L, Wu J, Xu S,
Liang X and Lou J: Identification of a panel of serum microRNAs as
biomarkers for early detection of lung adenocarcinoma. J Cancer.
8:48–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang AQ, Xi YN, Wang J, Sun L, Wei J, Lu
WY, Lan JY, Wang WW, Wang L and Wang LL: Predictive value of serum
microRNA-22 and microRNA-126 levels for non-small cell lung cancer
development and metastasis: A case-control study. Neoplasma.
64:453–459. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Foss KM, Sima C, Ugolini D, Neri M, Allen
KE and Weiss GJ: MiR-1254 and miR-574-5P: Serum-based microRNA
biomarkers for early-stage non-small cell lung cancer. J Thorac
Oncol. 6:482–488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang C, Ding M, Xia M, Chen S, Van Le A,
Soto-Gil R, Shen Y, Wang N, Wang J, Gu W, et al: A Five-miRNA panel
identified from a multicentric case-control study serves as a novel
diagnostic tool for ethnically diverse non-small-cell lung cancer
patients. EBioMedicine. 2:1377–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guan P, Yin Z, Li X, Wu W and Zhou B:
Meta-analysis of human lung cancer microRNA expression profiling
studies comparing cancer tissue with normal tissue. J Exp Clin
Cancer Res. 31:542012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang C, Sun C, Liang X, Xie S, Huang J and
Li D: Integrative analysis of microRNA and mRNA expression profiles
in non-small-cell lung cancer. Cancer Gene Ther. 23:90–97. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eilertsen M, Andersen S, Al-Saad S,
Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT
and Bremnes RM: Postive prognostic impact of miR-210 in non-small
cell lung cancer. Lung Cancer. 83:272–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duncavage E, Goodgame B, Sezhiyan A,
Govindan R and Pfeifer J: Use of microRNA expression levels to
predict outcomes in resected stage I non-small cell lung cancer. J
Thorac Oncol. 5:1755–1760. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao M, Hou D, Liang H, Gong F, Wang Y, Yan
X, Jiang X, Wang C, Zhang J, Zen K, et al: MiR-150 promotes the
proliferation and migration of lung cancer cells by targeting SRC
kinase signalling inhibitor 1. Eur J Cancer. 50:1013–1024. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mo D, Gu B, Gong X, Wu L, Wang H, Jiang Y,
Zhang B, Zhang M, Zhang Y, Xu J and Pan S: MiR-1290 is a potential
prognostic biomarker in non-small cell lung cancer. J Thorac Dis.
7:1570–1579. 2015.PubMed/NCBI
|
|
25
|
Liang B, Wang GX, Long G, Qiu JH and Hu
ZL: Tumor suppressor miR-22 suppresses lung cancer cell progression
through post-transcriptional regulation of ErbB3. J Cancer Res Clin
Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shin YM, Yun J, Lee OJ, Han HS, Lim SN, An
JY, Lee KH, Lee KM and Choe KH: Diagnostic value of circulating
extracellular miR-134, miR-183, and miR-22 levels in lung
adenocarcinoma-associated malignant pleural effusion. Cancer Res
Treat. 46:178–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu T, Chen W, Kong D, Li X, Lu H, Liu S,
Wang J, Du L, Kong Q, Huang X and Lu Z: MiR-25 targets the
modulator of apoptosis 1 gene in lung cancer. Carcinogenesis.
36:925–935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang P, Yang D, Zhang H, Wei X, Ma T,
Cheng Z, Hong Q, Hu J, Zhuo H, Song Y, et al: Early detection of
lung cancer in serum by a panel of microRNA biomarkers. Clin Lung
Cancer. 16:313–319.e1. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heegaard NH, Schetter AJ, Welsh JA, Yoneda
M, Bowman ED and Harris CC: Circulating miroRNA expression profiles
in early stage non-small cell lung cancer. Int J Cancer.
130:1378–1386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu W, He J, Chen D, Zhang B, Xu L, Ma H,
Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429
as potential biomarkers for detection of early stage non-small lung
cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boeri M, Verri C, Conta D, Roz L, Modena
P, Facchinetti F, Calabrò E, Croce CM, Pastorino U and Sozzi G:
MicroRNA signatures in tissues and plasma predict development and
prognosis of computed tomography detected lung cancer. Proc Natl
Acad Sci USA. 108:3713–3718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patnaik SK, Yendamuri S, Kannisto E,
Kucharczuk JC, Singhal S and Vachani A: MicroRNA expression
profiles of whole blood in lung adenocarcinoma. PLoS One.
7:e460452012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Long H, Wang Z, Chen J, Xiang T, Li Q,
Diao X and Zhu B: MicroRNA-214 promotes epithelial-mesenchymal
transition and metastasis in lung adenocarcinoma by targeting the
suppressor-of-fused protein (Sufu). Oncotarget. 6:38705–38718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim G, An HJ, Lee MJ, Song JY, Jeong JY,
Lee JH and Jeong HC: Hsa-miR-1246 and hsa-miR-1290 are associated
with stemness and invasiveness of non-small cell lung cancer. Lung
Cancer. 91:15–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rani S, Gately K, Crown J, O'Byrne K and
O'Driscoll L: Global analysis of serum microRNAs as potential
biomarkers for lung adenocarcinoma. Cancer Biol Ther. 14:1104–1112.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu S, Kong H, Hou Y, Ge D, Huang W, Ou J,
Yang D, Zhang L, Wu G, Song Y, et al: Two plasma microRNA panels
for diagnosis and subtype discrimination of lung cancer. Lung
Cancer. 123:44–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang W, Li H and Luo R: The microRNA-1246
promotes metastasis in non-small cell lung cancer by targeting
cytoplasmic polyadenylation element-binding protein 4. Diagn
Pathol. 10:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang N, Wei X and Xu L: MiR-150 promotes
the proliferation of lung cancer cells by targeting P53. FEBS Lett.
587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin QW, Sun XF, Yang GT, Li XB, Wu MS and
Zhao J: Increased expression of microRNA-150 is associated with
poor prognosis in non-small cell lung cancer. Int J Clin Exp
Pathol. 8:842–846. 2015.PubMed/NCBI
|
|
40
|
Tian F, Li R, Chen Z, Shen Y, Lu J, Xie X
and Ge Q: Differentially expressed miRNAs in tumor, adjacent, and
normal tissues of lung adenocarcinoma. Biomed Res Int.
2016:14282712016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma R, Wang C, Wang J, Wang D and Xu J:
MiRNA-mRNA interaction network in non-small cell lung cancer.
Interdiscip Sci. 8:209–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Goldstraw P: Staging Manual in Thoracic
Oncology. Orange Pakk, FL: Editorial Rx Press; pp. 57–65. 2009
|
|
43
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
DeLong ER, DeLong DM and Clarke-Pearson
DL: Comparing the area under two or more correlated receiver
operating characteristic curve: A nonparametric approach.
Biomentrics. 44:837–845. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou Q, Huang SX, Zhang F, Li SJ, Liu C,
Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel
potential biomarker for diagnosis and therapy in patients with
non-small cell lung cancer. Cell Prolif. 50:e123942017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Belinsky SA: Gene-promoter
hypermrthylation as a biomaker in lung cancer. Nat Rev Cancer.
4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu X, Qu J, Xue W, He L, Wang J, Xi X,
Liu X, Yin Y and Qu Y: Bioinformatics-based identification of
potential microRNA biomarkers in frequent and non-frequent
exacerbators of COPD. Int J Chron Obstruct Pulmon Dis.
13:1217–1228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kara M, Kirkil G and Kalemci S:
Differential expression of microRNAs in chronic obstructive
pulmonary disease. Adv Clin Exp Med. 25:21–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hermann S, Brandes F, Kirchner B,
Buschmann D, Borrmann M, Klein M, Kotschote S, Bonin M, Reithmair
M, Kaufmann I, et al: Diagnostic potential of circulating cell-free
microRNAs for comminity-acquired pneumonia and pneumonia-related
sepsis. J Cell Mol Med. 24:12054–12064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan
BS, Wang Q, Ding FH, Ou JX, Liu FL, et al: Role of a serum-based
biomarker panel in the early diagnosis of lung cancer for a cohort
of high-risk patients. Cancer. 121 (Suppl):S3113–S3121. 2015.
View Article : Google Scholar
|
|
51
|
Kosaka N, Iguchi H, Yoshioka Y, Takeshita
F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular
transfer of microRNAs in living cells. J Boil Chem.
285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schwarzenbach H, Nishida N, Calin GA and
Panted K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang X, Zhi X, Zhang Y, An G and Feng G:
Role of plasma microRNAs in the early diagnosis of non-small-cell
lung cancer: A case-control study. J Thorac Dis. 8:1645–1652. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xing L, Todd NW, Yu L, Fang H and Jiang F:
Early detection of squamous cell lung cancer in sputum by a panel
of microRNA markers. Mod Pathol. 23:1157–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim JO, Gazala S, Razzak R, Guo L, Ghosh
S, Roa WH and Béard EL: Non-small cell lung cancer detection using
microRNA expression profiling of bronchoalveolar lavage fluid and
sputum. Anticancer Res. 35:1873–1880. 2015.PubMed/NCBI
|
|
56
|
Zhang WC, Chi TM, Yang H, Nga ME, Lunny
DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, et al:
Tumor-initiating cell-specific miR-1246 and miR-1290 expression
converge to promote non-small cell lung cancer progression. Nat
Commun. 7:117022016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang L, Lin J, Ye Y, Oba T, Gentile E,
Lian J, Wang J, Zhao Y, Gu J, Wistuba II, et al: Serum microRNA-150
predicts prognosis for early-stage non-small cell lung cancer and
promotes tumor cell proliferation by targeting tumor suppressor
gene SRCIN1. Clin Pharmacol Ther. 103:1061–1073. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li H, Liu J, Cao W, Xiao X, Liang L,
Liu-Smith F, Wang W, Liu H, Zhou P, Ouyang R, et al:
C-myc/miR150/EPG5 axis mediated dysfunction of autophagy promotes
development of non-small cell lung cancer. Theranostics.
9:5135–5148. 2019. View Article : Google Scholar
|
|
59
|
Li C, Yin Y, Liu X, Xi X, Xue W and Qu Y:
Non-small cell lung cancer associated microRNA expression
signature: Integrated bioinformatic analysis, valilation and
clinical significance. Oncotarget. 8:24564–24578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li X and Wu X: MiR-21-5P promotes the
progression of non-small-cell lung cancer by regulating the
expression of SMAD7. Onco Targets Ther. 11:8445–8454. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bertol G, Cava C and Castigliohi I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ahmed EK, Fahmy SA, Effat H and Wahab AHA:
Circulating miR-210 and miR-1246 as potential biomarkers for
differentiating hepatocellular carcinoma from metastatic tumors in
the liver. J Med Biochem. 38:109–117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wei J, Yang L, Wu YN and Xu J: Serum
miR-1290 and miR-1246 as potential diagnostic biomarkers of human
pancreatic cancer. J Cancer. 11:1325–1333. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kobayashi M, Sawada K, Nakamura K,
Yoshimura A, Miyamoto M, Shimizu A, Ishida K, Nakatzuka E, Kodama
M, Hashimoto K, et al: Exosomal miR-1290 is a potential biomarker
of high-grade serous ovarian carcinoma and can disriminate patients
from those with malignanies of other histologial types. J Ovarian
Res. 11:812018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sur D, Burz C, Sabarimurugan S and Irimie
A: Diagnostic and prognostic significance of miR-150 in colorectal
cancer: A systematic review and meta-analysis. J Pers Med.
10:992020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kalogirou C, Ellinger J, Kristianse G,
Hatzichristodoulou G, Kubler H, Kneitz B, Busch J and Fendler A:
Identification of miR-21-5p and miR-210-3p serum levels as
biomarkers for patients with papillary renal cell carcinoma: A
multicenter analysis. Transl Androl Urol. 9:1314–1322. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Council for International Organizations of
Medical Sciences, . International ethical guidelines for biomedical
research involving human subjects. Bull Med Ethics. 182:17–23.
2002.PubMed/NCBI
|
|
68
|
World Medical Association, . Declaration
of Helsinki. 1964.http://www.wma.net/wp-content/uploads/2018/07/DoH-Jun1964.pdf
|
|
69
|
World Medical Association, . Declaration
of Helsinki. 2008.https://www.wma.net/wp-content/uploads/2018/07/DoH-Oct2008.pdf
|
